Arrowstreet Capital
LXRX icon

Arrowstreet Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Arrowstreet Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-47,849
Closed -$164K – 2406
2020
Q4 		$164K Sell
47,849
-1,055,858
-96% -$2.01M ﹤0.01% 2198
2020
Q3 		$1.59M Buy
1,103,707
+333,486
+43% +$594K ﹤0.01% 1659
2020
Q2 		$1.54M Buy
770,221
+22,552
+3% +$44.2K ﹤0.01% 1590
2020
Q1 		$1.46M Buy
747,669
+55,066
+8% +$164K ﹤0.01% 1176
2019
Q4 		$2.87M Buy
+692,603
New +$2.67M 0.01% 1024
2017
Q2 		– Sell
-514,658
Closed -$7.38M – 1219
2017
Q1 		$7.38M Buy
+514,658
New +$7.64M 0.03% 467
2016
Q4 		– Sell
-944,704
Closed -$17.1M – 2164
2016
Q3 		$17.1M Buy
944,704
+739,291
+360% +$11.9M 0.06% 332
2016
Q2 		$2.95M Buy
+205,413
New +$2.79M 0.01% 731
2016
Q1 		– Sell
-102,219
Closed -$1.36M – 1442
2015
Q4 		$1.36M Buy
+102,219
New +$1.26M 0.01% 904
2015
Q3 		– Sell
-62,745
Closed -$505K – 1433
2015
Q2 		$505K Buy
+62,745
New +$461K ﹤0.01% 978

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's LXRX Position: Q1 2021 in Review

Arrowstreet Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 47,849 shares — an estimated $164K sold.

Arrowstreet Capital first reported a position in LXRX in Q2 2015 and held it in 10 quarters. The position peaked at $17.1M in Q3 2016. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

  • Arrowstreet Capital reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 47,849 Lexicon Pharmaceuticals shares in Q1 2021, an estimated $164K.
  • Arrowstreet Capital first reported a position in Lexicon Pharmaceuticals in Q2 2015 and held it in 10 quarters.
  • Arrowstreet Capital's Lexicon Pharmaceuticals position peaked at $17.1M in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.